|Title||Investor presentation: Is Drug Discovery a Data Science Problem?|
|Title||Final Results - Year End 31 January 2022|
|Title||Interim results for six months ended 31 July 2021|
|Title||Investor presentation: Computational Drug Discovery - From Machine to Man|
Videos and podcasts
Computing The Future of Medicine Investor Presentation (November 2023)
Ali Mortazavi presents on e-therapeutics' HepNet computational platform, including integration of LLMs, and GalOmic RNAi therapeutic pipeline at the LSX Investival Showcase (November 2023)
AI's Game-Changing Impact on Drug Discovery (July 2023)
Ali Mortazavi, presents on AI's game-changing impact on drug discovery, and how we are leveraging the recent LLM breakthroughs at e-therapeutics, in an Investor Presentation via Investor Meet Company (July 2023)
Beyond Biotech Podcast Interview discussing recent fundraising and therapeutic pipeline progress
e-therapeutics CEO Ali Mortazavi talks to Jim Cornall editor of Labtiotech.eu about recent Company momentum and executing a differentiated strategy using computation to understand biology better and identify novel drug targets.
Proactive Interview: OTCQX Launch of Trading and RNAi Platform Progress
e-therapeutics plc's CEO Ali Mortazavi joins Proactive London after the recent launch of trading on the OTCQX Best Market under the ticker symbol ETXPF.
e-therapeutics plc's CEO Ali Mortazavi presenting at the Proactive One2One Virtual Forum, 25 February 2021
Downloadable slides from this presentation are available here.
Shares investor webinar with CEO Ali Mortazavi
Ali Mortazavi presents a Company overview at a Shares investor evening sponsored by A J Bell.
Shares Magazine Investor Evening Presentation
CEO and Chairman, Ali Mortazavi presenting at the Shares Magazine Investors Evening sponsored by A J Bell, 17 February 2021.